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Abstract 
We assessed the impact of antiviral preventive strategies on the incidence of herpes-simplex 
virus (HSV) and varicella-zoster virus (VZV) infections in a nationwide cohort of transplant 
recipients. Risk factors for the development of HSV/VZV infection were assessed by Cox PH 
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regression. We included 2781 patients (56% kidney, 20% liver, 10% lung, 7.3% heart, 6.7% 
others). Overall, 1264 (45%) patients received antiviral prophylaxis [(val)ganciclovir 
(n=1126) or (val)acyclovir (n=138)]. Incidences for HSV and VZV infections were 28.9 and 
12.1 cases per 1000 person-years, respectively. Incidence of HSV/VZV infections at 1-year 
post-transplant was 4.6% (95% CI 3.5-5.8) in patients receiving antiviral prophylaxis vs. 
12.3% (95% CI 10.7-14) in patients without prophylaxis; this was particularly observed for 
HSV infections: 3% (95% CI 2.2-4) vs. 9.8% (95% CI 8.4-11.4), respectively. A lower rate of 
HSV/VZV infections was also seen in donor or recipient CMV-positive patients receiving 
(val)ganciclovir prophylaxis as compared to a preemptive approach. Female gender (HR 
1.663, p=0.001), HSV seropositivity (HR 5.198, p<0.001), previous episodes of rejection 
(HR 1.95, p=0.004), and use of a preemptive approach (HR 2.841, p=0.017) were 
significantly associated with a higher risk for HSV infection. While HSV/VZV infections 
were common after transplantation, antiviral prophylaxis significantly reduced symptomatic 
HSV infections. 
 
INTRODUCTION 
Herpes simplex viruses type 1 and 2 (HSV-1 and -2), and varicella zoster virus (VZV) belong 
to the α-herpesvirinae subfamily and are characterized by establishing latency in the sensitive 
nerve root ganglia after primary infection (1,2). Both HSV and VZV infections are a common 
cause of mild to moderate illness in immunocompetent patients. In solid-organ transplant 
(SOT) recipients, as a consequence of impaired cell-mediated immunity on account of the 
immunosuppressive drugs, reactivation of HSV and VZV is common, and the clinical 
manifestation tends to be more severe and prolonged than in immunocompetent individuals 
(3,4).  
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The best strategy to prevent HSV and VZV infections after transplantation has not yet 
been clearly defined. In the absence of anti-herpes prophylaxis, up to 25-35% of seropositive 
patients will reactivate HSV, particularly in the first weeks following transplantation (5,6). 
Regarding VZV, the incidence of herpes zoster increases over months after transplantation, 
and may reach up to 15% of patients at 5 years post-transplant (7,8). Routine antiviral 
prophylaxis with ganciclovir or valganciclovir for the prevention of cytomegalovirus (CMV) 
infection has been linked to a lower HSV and VZV reactivation rates (9,10). In patients 
followed by a preemptive approach (i.e. monitoring of CMV replication and administration of 
an antiviral drug only in patients with active replication), or at low risk for CMV infection 
(i.e. recipient CMV seronegative receiving an organ from a CMV seronegative donor [D-/R-
]), specific anti-herpes prophylaxis with acyclovir or valacyclovir is generally recommended 
to reduce the incidence of symptomatic reactivation of these viruses (4,10). However, there 
are few data analyzing the impact of different anti-CMV preventive strategies using 
(val)ganciclovir on the incidence of HSV and VZV infection.  
Thus, the aim of this nationwide observational cohort study was to describe the 
clinical characteristics and analyze the risk factors of α-herpesvirus infections after 
transplantation, with the particular aim of assessing the impact of the different preventive 
strategies (prophylaxis with (val)ganciclovir vs. preemptive approach) against CMV infection 
on the incidence of symptomatic HSV and VZV infections.  
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MATERIAL AND METHODS 
Study design 
We conducted a nested project based on existing data of a multicentre, nationwide 
observational Swiss Transplant Cohort Study (STCS) (11). Specifically for the current study, 
we included all SOT recipients enrolled in the STCS from May 2008 to December 2014. All 
six Swiss transplant centers participate in the STCS, and for this period approximately 95% 
of all SOT recipients performed in Switzerland consented to be included. The STCS has been 
approved by the local Ethics Committee for Clinical Research of all participating centers, and 
patients gave written informed consent.   
 
Data collection 
Clinical data extracted from the STCS database included demographic characteristics, type of 
transplant, immunosuppressive regimens (induction and maintenance drugs), pre-transplant 
donor and recipient CMV serostatus as well as the pre-transplant HSV and VZV serologies of 
the recipient. Data recorded with regards to antiviral prevention were the type of antiviral 
drug (ganciclovir, valganciclovir, acyclovir, valacyclovir) and the length of prophylaxis 
duration. Data recorded on symptomatic HSV and VZV infection were the site of infection 
(mucocutaneous vs. non-mucocutaneous disease), number of episodes per patient, and the use 
of antiviral therapy for treating active infection. From September 2012, additional data were 
recorded including reduction of immunosuppression and need for hospitalization following 
an episode of infection. We also recorded the incidence of acute rejection, graft loss, and 
mortality.  
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Clinical definitions 
In the STCS, viral infections are classified according to standard definitions created by the 
Infectious Diseases Study Group of the STCS. Each infection episode was validated by a 
transplant infectious diseases specialist at each center. Symptomatic HSV or VZV disease 
was diagnosed when clinical manifestations were compatible with HSV or VZV infection, 
with or without microbiological confirmation by PCR. Non-mucocutaneous disease was 
diagnosed in case of clinical manifestations involving the gastro-intestinal tract (i.e: 
esophagus and stomach), the eye, the respiratory tract, and the central nervous system and/or 
a positive PCR in a tissue biopsy, corneal scraping or cerebro-spinal fluid, respectively. 
Patients with a positive PCR in blood were classified as having viremia, irrespective of the 
presence of other clinical manifestations. Because the extension of the involvement in 
mucocutaneous infections was not included in the STCS database, we used the need for 
antiviral therapy, reduction of immunosuppression, and hospitalization as surrogate markers 
for severity of infection.  
Antiviral prophylaxis for CMV was defined as the use of ganciclovir or valganciclovir 
started within the first 2 weeks post-transplantation. Patients without such a prophylactic 
treatment who were at risk for CMV disease (D+/R- and R+ patients) were considered as 
being managed by the preemptive approach, as described previously (12). CMV infection and 
disease were classified according the definitions published by the American Society of 
Transplantation guidelines (13). Anti-herpes prophylaxis was defined as the use of acyclovir 
or valacyclovir in patients not receiving anti-CMV prophylaxis. The use of universal 
prophylaxis or preemptive approach for CMV and anti-herpes prophylaxis was established 
according to each center protocol based on CMV serostatus. Because the antiviral 
prophylaxis (and the type of antiviral drug) depended on the CMV risk constellation, we 
defined four different groups: 1) CMV D-/R- patients receiving antiviral prophylaxis (either 
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anti-CMV or anti-herpes), 2) CMV D-/R- patients not receiving anti-CMV or anti-herpes 
prophylaxis, 3) CMV D+/R- or R+ patients receiving anti-CMV prophylaxis, and 4) CMV 
D+/R- or R+ patients managed by the preemptive approach. Because only 19 patients of the 
preemptive approach group received a specific anti-herpes prophylaxis, all D+/R- or R+ 
patients managed by a preemptive approach were analyzed as a single group irrespectively 
whether they have received anti-herpes prophylaxis or not. Acute rejection was defined for 
each organ following the standard international criteria (14).   
 
Statistical analysis 
A descriptive analysis was performed to determine the baseline characteristics (age, sex, 
organ transplanted, type of immunosuppressive therapy, CMV serostatus and HSV/VZV 
seropositivity), the transplant outcome variables (acute rejection, graft loss, death) and the 
episodes of HSV/VZV (median of episodes per patient, median time from transplantation, 
and clinical presentation) of the patients. Cumulative incidences were calculated by organ 
group to estimate the probability of first HSV or VZV infection events from transplant, 
treating death before an event as a competing risk, according to the antiviral prophylaxis 
used. The impact of the antiviral strategy on HSV or VZV reactivation was analyzed as time-
dependent risk factor using a Cox proportional hazard regression model adjusting for 
potential confounding factors such as type of organ, episodes of rejection, age, sex, CMV 
preventive strategy, CMV infection, and HSV or VZV seropositivity previous to transplant. 
The impact of the duration of antiviral prophylaxis on the probability of HSV or VZV 
infection was assessed by logistic regression. All analyses were performed with the statistical 
software R version 3.2.1.  (R Development 2012 Core Team. A language and environment 
for statistical computing. Available from: http://www.R-project.org 2012).  
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RESULTS 
Study population 
A total of 2781 SOT recipients (56% kidney, 20% liver, 10% lung, 7.3% heart, 6.7% others) 
were included in the study. The median age was 54 years (IQR 42-62) and 64% were male. 
Seventy-six percent of patients (1643/2155 of patients with available serology) were 
seropositive for HSV and 95% of the patients (2358/2477) were seropositive for VZV at the 
time of transplant. Overall, 1264 (45%) patients received antiviral prophylaxis (with either 
(val)ganciclovir [n=1126] or (val)acyclovir [n=138]) for a mean duration of 144 days 
(kidney: 117 days, liver: 118 days, lung: 237 days, and heart: 138 days). Baseline 
characteristics and outcomes of the patients according to the development of HSV, VZV or 
both HSV/VZV infections are detailed in Table 1. The calculated incidences were 28.9 cases 
per 1000 person-years of follow-up for HSV infection and 12.1 cases per 1000 person-years 
of follow-up for VZV infection.  
 
Herpes simplex virus infection 
The clinical characteristics of HSV infections are described in Table 2. Overall, 247 (8.9%) 
patients developed a total of 289 episodes of symptomatic HSV infection. Eighteen patients 
developed both HSV and VZV infections. The incidence at 1, 3 and 6 years post-transplant of 
first HSV infection was 6.7% (95% CI 5.8-7.7), 8.7% (95% CI 7.6-9.8) and 9.9% (95% CI 
8.7-11.2), respectively (Figure 1), with a median time of onset of 66 days after 
transplantation (IQR 21-336). The incidence by type of organ at 1 year post-transplantation 
was 9.4% in heart, 8.4% in liver, 6.5% in kidney, and 1.8% in lung transplant recipients. 
Overall, 86% of HSV infections were episodes of mucocutaneous disease. Episodes of non-
mucocutaneous disease included 16 infections of the gastrointestinal tract (40%), 12 episodes 
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of keratitis (30%), 6 episodes of respiratory tract infection (15%), and one episode of central 
nervous system (CNS) infection (2.5%).  
 
Varicella-zoster virus infection 
One hundred-ten patients (4.0%) developed VZV infections (including the 18 patients who 
additionally developed HSV infection), for a total of 121 episodes (Table 2).  The incidence 
of VZV infection at 1, 3 and 6 years post-transplant was 2.1% (95% CI 1.6-2.7), 3.5% (95% 
CI 2.8-4.2) and 4.4% (95% CI 3.5-5.4), respectively (Figure 1). The median time of onset 
was 249 days after transplantation (IQR 65-738). The incidence of VZV infection by 
transplant type at 1 year post-transplant was 2.3% in kidney, 1.6% in liver, 5.5% in heart, and 
0% in lung transplant recipients. Six cases of non-mucocutaneous involvement were 
diagnosed, including 3 episodes of CNS disease, 2 of keratitis, and 1 case of VZV viremia.  
 
Impact of the antiviral preventive strategy on HSV and VZV infections  
We analyzed the incidence of both HSV and VZV infections according to the CMV 
serostatus and the antiviral preventive strategy used after transplant (Figure 2). Overall, the 
incidences of HSV/VZV infections at 1 year post-transplant were 4.6% (95% CI 3.5-5.8) in 
patients receiving antiviral prophylaxis [either (val)ganciclovir of (val)acyclovir] vs. 12.3% 
(95% CI 10.7-14) in patients without any antiviral prophylaxis (p<0.001) (Figure 2A). The 
impact of antiviral prophylaxis was more manifest when looking specifically at HSV 
infection: 3% (95% CI 2.2-4) vs. 9.8% (95% CI 8.4-11.4) in patients with and without 
prophylaxis, respectively.  
According to CMV serostatus, in D+/R- or R+ patients the incidences of HSV/VZV 
infections were 4.5% (95% CI 3.4-5.9) in patients receiving (val)-ganciclovir prophylaxis and 
13.2% (95% CI 11.3-15.3) in patients followed by the preemptive approach (p<0.001). In D-
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/R- patients, the incidence of HSV/VZV infection at 1 year post-transplantation was 2.5% 
(95% CI 0.8-5.9) vs. 10.4% (95% CI 7.7-13.7) in patients with and without any antiviral 
prophylaxis (p=0.01), respectively (Figure 2B).  
When looking separately according to each viral infection, the incidence of HSV 
infection was 2.9% (95% CI 2.1-4.1) in CMV D+/R- or R+ patients receiving (val)-
ganciclovir prophylaxis vs. 10.6% (95% CI 8.9-12.5) in patients followed by the preemptive 
approach (p<0.001, prophylaxis vs. preemptive); and 1.2% (95% CI 0.2-4.1) in CMV D-/R- 
patients receiving antiviral prophylaxis vs. 8.2% (95% CI 5.8-11.1) in D-/R- patients without 
antiviral prophylaxis (p=0.01, with vs. without prophylaxis) (Figure 2C). There were no 
differences in the incidence of VZV infection according to the antiviral preventive strategy 
received (p=0.53) (Figure 2D). 
 
Risk factors for HSV and VZV infections 
Variables significantly associated with a higher risk for HSV infection in the multivariate 
analysis were female gender, HSV seropositivity, previous episodes of acute rejection, and 
the use of a preemptive approach for CMV prevention in D+/R- or R+ patients as compared 
to the reference group of D-/R- with antiviral prophylaxis (Table 3). Previous episodes of 
CMV infection were a significant risk factor for HSV infection in the univariate, but not in 
the multivariate model.   
 Because the impact of antiviral prophylaxis on HSV infections seemed to be more 
important early after transplant, we built a new Cox PH model taking into consideration the 
period post transplant (i.e. <6 months vs. > 6 months). As compared to the reference group of 
D-/R- with antiviral prophylaxis, the risk for HSV infection in D+/R- and R+ patients 
followed by the preemptive approach was only significant during the first 6 months post 
transplant (HR 6.102 [95% CI 1.469 - 25.353], p=0.013), as compared to > 6 months post 
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transplant (HR 1.218 [95% CI 0.417 - 3.383], p=0.719). The impact of being seropositive for 
HSV was also higher during the first 6 months post transplant (HR 7.582 [95% CI 3.072 - 
18.716], p<0.001), than later on (HR 3.102 [95% CI 1.313 - 7.329] p=0.01). 
For VZV infection, as compared to kidney transplantation, heart transplantation was 
associated with a higher risk and lung transplantation with a lower risk of VZV infection, 
although this was not statistically significant. Age, sex, previous episodes of rejection, VZV 
seropositivity, and the antiviral preventive strategy were not significantly associated as 
risk/protective factors for VZV infection in this model (Table 4).  
Of note, no particular induction or maintenance immunosuppressive regimen was 
associated with a higher risk for the development of HSV or VZV infections. 
 
Impact of the duration of antiviral prophylaxis on the incidence of HSV and VZV 
infections 
We next assessed in a logistic regression the risk of HSV and VZV infections according 
whether the patients had received no antiviral prophylaxis, less than 3 months, between 3-6 
months, or more than 6 months of antiviral prophylaxis (Table 5). We found that the longer 
the duration of prophylaxis, the lower the risk of HSV infection. We did not observe any 
difference in the incidence of VZV according to the duration of antiviral prophylaxis. 
 
DISCUSSION 
Symptomatic HSV and VZV clinical infections were relatively frequent in the Swiss 
population of SOT recipients, with an incidence during the first year post transplant ranging 
from 1.8% to 9.4% for HSV and 0% to 5.5% for VZV, according to the type of organ 
transplant. These numbers are somewhat lower than those reported in other cohorts 
(7,8,15,16), possibly reflecting a continuous improvement in the prevention and management 
of post transplant viral infections in the current era of transplant medicine.  
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We found a lower incidence of mostly HSV infections in patients receiving antiviral 
prophylaxis as compared to patients followed by the preemptive approach or not receiving 
specific anti-herpes prophylaxis. There are few data in the literature on the impact of antiviral 
preventive strategies (mostly aimed at preventing CMV infection) on -herpesvirus infection. 
In a recent meta-analysis evaluating the efficacy of CMV preventive strategies in SOT 
recipients (17), both antiviral prophylaxis and preemptive therapy showed similar efficacy in 
preventing HSV and VZV infections. However, another study including 363 kidney 
transplant recipients analyzed the incidence of VZV reactivation according to the type of 
antiviral prophylaxis used. Patients were categorized into 3 groups: preemptive therapy, 
universal prophylaxis <3 months, and universal prophylaxis >3 months. In this setting, 
patients followed by preemptive therapy had a higher incidence of infection compared with 
the others groups (80 vs. 54.5 vs. 13 cases per 1000 person-years) (18). This is in 
concordance with our results, where the probability of α-herpesvirus infection was higher in 
patients without antiviral prophylaxis, in particular in patients followed by preemptive 
therapy, as compared to patients receiving antiviral drugs. We also observed in our study that 
patients receiving more than three or six month of prophylaxis had the lowest risk for the 
development of HSV infection. The impact of antiviral prophylaxis was mainly seen for HSV 
infection, likely due to the lower number of VZV infections and the fact that VZV infections 
appeared later on after transplantation, when most antiviral drugs were no longer prescribed 
as prophylaxis. This could be also explained by the presence of natural polymorphism of 
VZV thymidine kinase and DNA polymerase found in in vitro studies, conferring a lower 
intrinsic antiviral activity of ganciclovir against VZV as compared to HSV (19, 20).  
Overall, our data indicate that specific anti-herpes prophylaxis in patients not 
receiving anti-CMV drugs may further reduce the incidence of HSV and VZV infections. Of 
note, the antiviral agents approved for the prevention and treatment of herpesvirus infections 
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act at the same step of virus replication, inhibiting the viral DNA polymerase. Acyclovir and 
ganciclovir require phosphorylation to be activated by a thymidine kinase in HSV or VZV 
and by its homolog UL97 protein kinase in CMV. Because acyclovir and valacyclovir are 
usually well tolerated and are less expensive than anti-CMV drugs, this strategy might be 
cost-effective in the setting of organ transplantation. This recommendation can be particularly 
important in case of HSV seropositivity, female patients, and after therapy of acute rejection, 
the risk factors for HSV infection identified in our study. We found a surprising lower 
incidence of HSV and VZV infections in lung transplant recipients as compared to other 
types of transplant. Although higher rates of infection have been previously reported in lung 
transplant recipients (8,21–24), our results can be explained by a longer duration of antiviral 
prophylaxis used in these patients as compared to other organ transplants. Finally, we found 
that both (val)-acyclovir and (val)-ganciclovir seem equally effective for the prevention of -
herpesvirus infection, an expected result but not extensively reported in the literature.  
While the most common clinical presentation of α-herpesvirus infection was 
mucocutaneous, non-mucocutaneous involvement – feared due to its more complicated 
course - was detected in 10% involving infections of the gastrointestinal tract and keratitis for 
HSV. Of note, the data included in the STCS database did not allow us to estimate the 
severity of the clinical presentation, in particular regarding the rate of disseminated herpes 
zoster and the subsequent incidence of post herpetic neuralgia. However, we could estimate 
that these infections were associated with a significant burden of disease, as more than 93% 
of the patients received antiviral treatment and between 8% and 17% of them required 
hospitalization.  
Current immunosuppressive regimens have been related with a higher incidence and 
more severe clinical manifestations of α-herpesvirus reactivation in some studies. 
Mycophenolate mofetil (MMF) was identified as an independent risk factor for VZV 
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reactivation after liver transplantation (7,21,25). Because the majority of the patients received 
MMF as part of the immunosuppressive regimen, it was difficult to assess the impact of 
MMF on the risk of infection in our study. Gourishankar et al. found that the use of induction 
therapy was a risk factor for VZV reactivation after transplantation (7), but this was not 
confirmed in the present study. Also, we did not identify the use of mTOR inhibitors, an 
immunosuppressive drug with antiviral properties, as a protective factor for the development 
of HSV and VZV infections.  
This study has several limitations. First and foremost, data on the severity and 
complications of the mucocutaneous involvement in VZV and HSV infection were not 
available in the STCS database, so that we were not able to estimate the true burden of 
disease in view of a potential recommendation for the use of anti-herpes prophylaxis in all 
patients not receiving anti-CMV drugs. We were not able either to differentiate between 
HSV-1 and HSV-2 infections, due to the absence of information on the localization of the 
mucocutaneous disease and the type of viruses involved. Also, we cannot exclude that some 
infections were underreported, particularly months or years after transplant, when patients are 
not exclusively followed at the transplant center. Finally, because very few D+/R- or R+ 
patients followed by the preemptive approach for CMV received anti-herpes prophylaxis, we 
were not able to analyze them separately from those who did not receive any antiviral drug. 
Nevertheless, this is probably the largest cohort of SOT recipients with a long follow-up 
where the incidence and risk factors of these common viral infections have been assessed, 
and the results from this study may help to delineate current guidelines for the management 
of HSV or VZV infection in the transplant population (4,26). 
In conclusion, in this large nationwide cohort of SOT recipients, HSV and VZV 
infections were relatively common, with several cases of non-mucocutaneous involvement. 
Antiviral prophylaxis with (val)ganciclovir or (val)acyclovir had a significant impact on 
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reducing the incidence of HSV infection after transplantation. Specific anti-herpes 
prophylaxis might be recommended in patients not otherwise receiving anti-CMV drugs, 
especially after intensification of immunosuppression for acute rejection. 
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Figure legends 
Figure 1. Cumulative incidence of HSV and VZV infections after transplantation. HSV, 
herpes-simplex virus; VZV, varicella-zoster virus. 
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Figure 2. Probability of HSV and VZV infections after transplantation according to the 
CMV serostatus and the antiviral preventive strategy. Probability of HSV or VZV 
infection in patients with (light blue line) or without (green line) antiviral prophylaxis 
(p<0.001, with vs. without prophylaxis) (A). Probability of  infection in CMV D-/R- patients 
receiving antiviral prophylaxis (yellow line), CMV D+/R- or R+ patients receiving antiviral 
prophylaxis (grey line), CMV D-/R- patients not receiving antiviral prophylaxis (green line), 
and CMV D+/R- or R+ followed by the preemptive approach (magenta line): HSV or VZV 
infection (p<0.001, all four groups) (B); HSV infection (p<0.001, all four groups) (C); VZV 
infection (p<0.53, all four groups) (D). CMV, cytomegalovirus; HSV, herpes-simplex virus; 
VZV, varicella-zoster virus. 
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Table 1. Baseline characteristics and outcomes of patients included in the analysis 
according to whether they developed HSV, VZV, or both infections  
 
Characteristics 
 
No 
HSV/VZV 
infection 
n=2442 
(88%) 
HSV 
infection 
n=229 
(8.2%) 
VZV 
infection 
n=92 
(3.3%) 
HSV and 
VZV 
infection 
n=18 (0.6%) 
Follow-up, years, median (IQR) 3.2 (1.6, 5.1) 4.2 (2.2, 
5.8) 
5 (3.1, 6.1) 4.6 (3.2, 5.8) 
Sex, male, n (%) 1571 (64) 129 (56) 62 (67) 8 (44) 
Age at transplant, years, median (IQR) 54 (42-62) 55 (43-61) 55 (40-62) 53 (40-64) 
Transplant, n (%) 
Kidney 
Liver 
Lung  
Heart 
Others 
 
1352 (55) 
491 (20) 
270 (11) 
166 (6.8) 
163 (6.7) 
 
131 (57) 
51 (22) 
8 (3.5) 
19 (8.3) 
20 (8.7) 
 
56 (61) 
15 (16) 
4 (4.3) 
14 (15) 
3 (3.3) 
 
13 (72) 
2 (11) 
0 
3 (17) 
0 
Induction, n (%) 
Basiliximab 
Rabbit-antithymocyte globulins  
Others 
2130 (87) 
1599 (75) 
596 (28) 
183 (8.6) 
194 (85) 
154 (79) 
41 (21) 
18 (9.3) 
81 (88) 
62 (77) 
20 (25) 
5 (6.1) 
15 (83) 
12 (80) 
3 (20) 
1 (6.7) 
Maintenance immunosuppression, n 
(%)  
Tacrolimus 
Cyclosporine 
MMF/MPA 
m-TOR inhibitors 
Steroids 
Other 
 
1723 (71) 
622 (26) 
2207 (91) 
99 (4.1) 
2252 (93) 
56 (2.3) 
 
150 (66) 
70 (31) 
210 (93) 
8 (3.5) 
214 (94) 
3 (1.3) 
 
62 (67) 
26 (28) 
85 (92) 
7 (7.6) 
92 (100) 
2 (2.2) 
 
10 (59) 
7 (41) 
17 (100) 
1 (5.9) 
17 (100) 
0 
HSV serology, n (%) 
Positive 
Negative 
Missing 
 
1418 (58) 
486 (20) 
538 (22) 
 
157 (69) 
9 (3.9) 
63 (28) 
 
56 (61) 
15 (16) 
21 (23) 
 
12 (67) 
2 (7.4) 
4 (22) 
VZV serology, n (%) 
Positive 
Negative 
Missing 
 
2074 (85) 
108 (4.4) 
260 (11) 
 
185 (81) 
9 (3.9) 
35 (15) 
 
83 (90) 
1 (1.1) 
8 (8.7) 
 
16 (89) 
1 (5.5) 
1 (5.5) 
CMV serostatus, n (%) 
D+/R- 
D+/R+ 
D-/R+ 
D-/R- 
 
509 (21) 
812 (33) 
619 (25) 
502 (21) 
 
23 (10) 
111 (49) 
53 (23) 
42 (18) 
 
16 (17) 
33 (36) 
28 (30) 
15 (16) 
 
2 (11) 
7 (39) 
5 (28) 
4 (22) 
CMV prevention in D+/R-  or R+ 
patients , n (%) 
Prophylaxis 
Preemptive (including anti-herpes 
prophylaxis) 
 
1007 (52) 
933 (48) 
 
41 (22) 
146 (78) 
 
36 (47) 
41 (53) 
 
1 (7.1) 
13 (86) 
Antiviral prophylaxis in D-/R- patients, 
n (%) 
Prophylaxis 
No prophylaxis 
 
151 (30) 
351 (70) 
 
5 (12) 
37 (88) 
 
3 (20) 
12 (80) 
 
1 (25) 
3 (75) 
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Type of antiviral prophylaxis, n (%) 
(n=1264) 
Ganciclovir 
Valganciclovir 
Acyclovir 
Valacyclovir 
1171 
172 (15) 
1003 (86) 
4 (0.34) 
122 (9) 
51 
3 (5.8)  
41 (80) 
0 (0) 
8 (14) 
40 
2 (5) 
35 (87) 
0 (0) 
4 (10) 
2 
0 (0) 
2 (100) 
0 (0) 
0 (0) 
Duration of antiviral prophylaxis, days, 
mean (SD) 
147 (202)
  
99 (57) 122 (80)
  
63 (47) 
Duration of antiviral prophylaxis, n (%) 
< 3 months of prophylaxis 
3-6 months of prophylaxis 
> 6 months of prophylaxis 
 
431 (18) 
560 (23) 
180 (7.4) 
 
31 (13.5) 
16 (7) 
4 (1.7) 
 
18 (20) 
18 (20) 
4 (4.3) 
 
1 (5.6) 
1 (5.6) 
0 (0) 
CMV infection, n (%) 
CMV infection previous to 
HSV/VZV infection, n (%) 
778 (32) 
- 
108 (47) 
57 (53) 
47 (51) 
30 (64) 
8 (44) 
2 (25) 
CMV disease, n (%) 
CMV infection previous to 
HSV/VZV infection, n (%) 
164 (6.7) 
- 
30 (13) 
14 (47) 
8 (8.7) 
4 (50) 
2 (11) 
0 (0) 
Acute rejection, n (%) 788 (32) 90 (40) 45 (49) 9 (50) 
Graft loss, n (%) 166 (6.8) 22 (9.6) 7 (7.6) 1 (5.6) 
Death, n (%) 301 (12) 29 (13) 6 (6.5) 1 (5.6) 
CMV, cytomegalovirus; D, donor; R, recipient; IQR, interquartile range; MMF, 
mycophenolate mofetil; MPA, mycophenolic acid; m-TOR, mammalian target of rapamycin. 
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Table 2. Clinical manifestation and management of HSV and VZV infections  
 HSV infection VZV infection 
Number of patients (% of all) 247 (8.9%) 110 (4.0%) 
Number of infections 289 121 
Time of onset from transplantation, days, 
median (IQR) 
 
66 (21-336) 
 
249 (65-738) 
Seropositivity at the time of transplant 169/180 (94%) 99/101 (98%) 
Mucocutaneous disease, n (%) 
Non-mucocutaneous disease, n 
(%) 
Gastrointestinal 
Ocular 
Viremia 
Central nervous system 
Respiratory tract 
249 (86%) 
40 (14%) 
16 (40%) 
12 (30%) 
5 (13%) 
1 (2.5%) 
6 (15%) 
115 (95%) 
6 (5%) 
0 (0%) 
2 (33%) 
1 (17%) 
3 (50%) 
0 (0%) 
Antiviral therapy, n (%) 265 (93%) 119 (98%) 
Reduction of immunosupression, n (%) 6/143 (4.2%) 3/66 (4.5%) 
Hospitalization due to HSV or VZV 
infection, n (%) 
  
12/143 (8.3%) 
 
11/66 (17%) 
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Table 3. Risk factors associated with HSV infection after transplantation 
 Univariate analysis Multivariate analysis 
Variable HR (95% CI) P HR (95% CI) P 
Age 1.006  (0.997-1.014) 0.188 0.999 (0.989-1.01) 0.906 
Gender 
Male 
Female 
 
reference 
1.434 
 
 
(1.114-1.845) 
 
 
0.005 
 
 
1.663 
 
 
(1.229-2.25) 
 
 
0.001 
HSV serostatus 
Negative 
Positive 
 
reference 
5.082 
 
 
(2.761- 9.354) 
 
 
<0.001 
 
 
5.198 
 
 
(2.787-9.693) 
 
 
<0.001 
Organ Transplant 
Kidney 
Heart 
Liver 
Lung 
Other 
 
reference 
1.422 
1.09 
0.321 
1.222 
 
 
(0.907-2.228) 
(0.793-1.497) 
(0.157-0.654) 
(0.765-1.951) 
 
 
0.125 
0.597 
0.002 
0.402 
 
 
1.342 
0.801 
0.651 
1.284 
 
 
(0.817-2.205) 
(0.553-1.161) 
(0.301-1.408) 
(0.771-2.14) 
 
 
0.245 
0.242 
0.275 
0.336 
CMV preventive strategy 
D-/R- with antiviral prophylaxis 
D-/R- without antiviral prophylaxis 
D+/R- or R+ anti-CMV prophylaxis 
D+/R- or R+ preemptive approach 
 
reference 
2.758 
1.212 
3.827 
 
 
(1.17-6.506) 
(0.519-2.828) 
(1.691-8.661) 
 
 
0.02 
0.657 
0.001 
 
 
2.227 
0.63 
2.841 
 
 
(0.894-5.549) 
(0.259-1.533) 
(1.206-6.689) 
 
 
0.086 
0.309 
0.017 
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Previous CMV infection 
No 
Yes 
 
reference 
2.567 
 
 
(1.544-4.269) 
 
 
<0.001 
 
reference 
1.534 
 
 
(0.808 – 2.91) 
 
 
0.19 
Induction therapy 
No 
Yes  
 
reference 
0.803 
 
 
(0.568-1.136) 
 
 
0.215 
   
Maintenance immunosuppression 
Tacrolimus 
MMF 
mTOR inhibitors 
 
0.794 
0.962 
1.246 
 
(0.61-1.035) 
(0.726-1.274) 
(0.723-2.144) 
 
0.089 
0.785 
0.428 
   
Previous episode of acute rejection 
No 
Yes 
 
reference 
1.904 
 
 
(1.278-2.839) 
 
 
0.002 
 
 
1.95 
 
 
(1.235-3.077) 
 
 
0.004 
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Table 4. Risk factors associated with VZV infection after transplantation  
 Univariate analysis Multivariate analysis 
Variable HR (95% CI) P HR (95% CI) P 
Age  1.003 (0.991-1.016) 0.604 1.004 (0.99-1.018) 0.602 
Gender 
Male 
Female 
 
reference 
0.88 
 
 
(0.576-1.344) 
 
 
0.555 
 
 
0.958 
 
 
(0.609-1.506) 
 
 
0.853 
VZV serostatus 
Negative 
Positive 
 
reference 
4.75 
 
 
(0.663-34.153) 
 
 
0.121 
 
 
4.103 
 
 
(0.567-29.696) 
 
 
0.162 
Organ Transplant 
Kidney 
Heart 
Liver 
Lung 
Other 
 
reference 
2.25 
0.814 
0.39 
0.436 
 
 
(1.257-4.028) 
(0.469-1.414) 
(0.142-1.073) 
(0.137-1.39) 
 
 
0.006 
0.466 
0.068 
0.16 
 
 
1.783 
0.713 
0.428 
0.444 
 
 
(0.942-3.376) 
(0.388-1.309) 
(0.151-1.218) 
(0.139-1.422) 
 
 
0.076 
0.275 
0.112 
0.172 
CMV preventive strategy 
D-/R- with antiviral prophylaxis 
D-/R- without antiviral prophylaxis 
D+/R- or R+ anti-CMV prophylaxis 
D+/R- or R+ preemptive approach 
 
reference 
1.816 
1.886 
2.313 
 
 
(0.517-6.372) 
(0.582-6.108) 
(0.718-7.457) 
 
 
0.352 
0.29 
0.16 
 
 
1.701 
1.479 
1.874 
 
 
(0.477-6.068) 
(0.452-4.844) 
(0.565-6.221) 
 
 
0.413 
0.518 
0.305 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Previous CMV infection 
No 
Yes 
 
Reference 
1.173 
 
 
(0.365 - 3.771) 
 
 
0.789 
 
reference 
1.082 
 
 
(0.331-3.539) 
 
 
0.896 
Induction therapy 
No  
Yes 
 
reference 
1.063 
 
 
(0.581-1.946) 
 
 
0.843 
   
Maintenance immunosuppression 
Tacrolimus 
MMF 
mTOR inhibitors 
 
0.794 
1.292 
1.561 
 
(0.521-1.208) 
(0.813-2.055) 
(0.756-3.226) 
 
0.281 
0.278 
0.229 
   
Previous episode of acute rejection 
No 
Yes 
 
reference 
2.423 
 
 
(1.239-4.74) 
 
 
0.01 
 
 
1.927 
 
 
(0.93-3.991) 
 
 
0.078 
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Table 5. Logistic regression model of the probability of HSV and VZV according to the 
duration of antiviral prophylaxis 
 
 HSV infection VZV infection 
Duration of antiviral 
prophylaxis 
Odds 
ratio 
95% CI p-value Odds ratio 95% CI p-value 
< 3months vs. no 
prophylaxis 
0.507 
(0.345 - 
0.744) 
0.001 0.987 
(0.575 - 
1.693) 
0.961 
3-6 months vs. no 
prophylaxis 
0.193 
(0.115 -
0.324) 
<0.001 0.803 
(0.469 - 
1.376) 
0.424 
> 6 months vs. no 
prophylaxis 
0.154 
(0.056 - 
0.419) 
<0.001 0.567 
(0.203 - 
1.581) 
0.278 
3-6 months vs. < 3 
months 
0.381 (0.207 - 0.7) 0.002 0.814 
(0.419 - 
1.582) 
0.544 
> 6 months vs. < 3 
months 
0.303 
(0.106 - 
0.869) 
0.026 0.575 
(0.192 - 
1.721) 
0.322 
> 6 months vs. 3-6 
months 
0.797 
(0.263 - 
2.414) 
0.688 0.706 
(0.236 - 
2.113) 
0.534 
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